权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A microphysiological system of tendon inflammation and fibrosis for drug screening and efficacy testing

用于药物筛选和疗效测试的肌腱炎症和纤维化的微生理系统

基本信息

批准号：
10674534
负责人：
Hani A Awad
金额：
$ 72.19万
依托单位：
UNIVERSITY OF ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-08-15 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10674534
关键词：
3-Dimensional Acceleration Acute Adhesions Antibodies Biological Biological Assay Biological Markers Biological Models Blood Tests Blood Vessels Blood flow Cell Cycle Regulation Cells Chronic Cicatrix Circulation Clinical Clinical Trials Collagen Complex Confocal Microscopy Connective and Soft Tissue Detection Devices Disease Disease model Dose Drug Screening Endothelial Cells Endothelium Engineering Enzyme-Linked Immunosorbent Assay Evaluation Extracellular Matrix Extravasation FDA approved FRAP1 gene Fibroblasts Fibrosis Flexor Gamma-H2AX Gene set enrichment analysis Goals Health Human Hydrogels Image Immunology Impairment In Situ Infiltration Inflammation Inflammation Mediators Inflammatory Intervention Trial Label Libraries Link Macrophage Measurement Measures Mechanics Mediating Membrane Microfabrication Microfluidic Microchips Microfluidics Microscopic Microscopy Molecular Mus Musculoskeletal Myofibroblast Nanoporous Operative Surgical Procedures Optics Outcome PI3K/AKT Paracrine Communication Pathology Patients Periodicity Permeability Pharmaceutical Preparations Phase Phenotype Porosity Procedures Process Protein Secretion Publishing Replacement Arthroplasty Role SDZ RAD Safety Sampling Sensitivity and Specificity Serum Side Signal Transduction Silicon Sirolimus Spinal Fusion System Tendinopathy Tendon Injuries Tendon structure Testing Therapeutic Time Tissue Engineering Tissues Transforming Growth Factor beta Translating Vascular Endothelial Cell biological development biomarker selection cell motility clinically relevant design drug candidate drug discovery drug efficacy druggable target efficacy evaluation efficacy testing experience healing high throughput screening human tissue improved induced pluripotent stem cell induced pluripotent stem cell technology inhibitor injured innovation intercellular communication joint function mTOR Inhibitor manufacture meter microphysiology system microscopic imaging mouse model nano nanofabrication next generation sequencing organ on a chip photonics preclinical trial primary outcome programs regenerative therapy repaired secondary outcome senescence sensor sensor technology virtual clinical trial

项目摘要

Acute and chronic tendon injuries are among the most common musculoskeletal health problems. Typically, an injured tendon experiences fibrotic scarring that leaves the tissue mechanically compromised and prone to debilitating adhesions that impair joint function. In a fibrotic tendon scar, the cell-cell and paracrine signaling between inflammatory cells, such as macrophages, and tendon fibroblasts activate the latter into fibroproliferative myofibroblasts, ultimately differentiating into a senescent phenotype. Our previous studies using next-generation sequencing and gene set enrichment analysis mechanistically linked fibrosis and senescence in injured mouse tendons with TGF-beta activated mTOR signaling. To further elucidate this pathology, the goal of this proposal is to engineer a microfluidic human tendon-on-chip (hToC) system and use it to more accurately model the biological aspects of the inflammation and fibrosis in injured tendons. In the UG3 phase of this proposal, the chip will be fabricated featuring a multicompartmental design and microfluidic channels to incorporate a fibroblast-seeded collagen hydrogel and simulate vascular blood flow, respectively. Ultrathin, highly permeable, and optically transparent porous silicon membranes (SiM) will separate the hydrogel from circulation and provide a substrate for an endothelial barrier in between. The signaling between the fibroblasts, hydrogel-resident- and circulating-macrophages, and endothelial cells will be enabled through nanoporous SiM (~60 nm), while a microporous SiM (~ 8 µm) will allow extravasation of circulating macrophages and infiltration of the hydrogel under TGF-beta stimulation. To allow for a patient-centric chip, tendon fibroblasts will be used to create the tendon hydrogel and to reprogram donor-matching iPSCs to derive the endothelial cells and macrophages, respectively. An additional innovation will be the integration of label- free photonic sensors into the microfluidic device to allow on-chip sensing, which has been long appreciated as a critical, unmet need for organ-on-chip devices. The UG3 studies will use the chip to validate the role of mTOR in the disease model and identify biologically relevant biomarkers. In the UH3 phase, we will utilize the chip as a pre-clinical trial platform for testing efficacy and safety of FDA-approved mTOR inhibitors as potential disease modifying drugs, and as a drug screening platform to identify and prioritize safer and more potent inhibitors of mTOR and senescence in tendon injury for clinical trials. To successfully complete this innovative project, we have assembled a team of accomplished experts in tendon tissue engineering and surgery, immunology, iPSC technology, GMP cell manufacturing, nano- and micro-fabrication, sensor technology, and high throughput screening. The proposed studies will develop a human microphysiological system to catalyze clinical trials and accelerate drug discovery for acute and chronic tendon injuries.

急性和慢性肌腱损伤是最常见的肌肉骨骼健康问题之一。通常,一个